Financials
Financial year 2025
H & H PHARMACEUTICALS from Nivelles, company number BE0759775660, closed financial year 2025 with a result of € 8.4 million after tax. For that financial year H & H PHARMACEUTICALS recorded revenue of € 1.7 million and equity of € 27.8 million. Compared with financial year 2024, the result moved from € 3.4 million to € 8.4 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 20, 2026.
€ 27.8 million
▲ 43% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8.4 million
▲ 144% vs 2024
Profit after tax over the fiscal year.
€ 5.3 million
▲ 158% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 27.8 million.
Debts at end 2025
€ 18.5 million
▼ 15% vs 2024
€ 3.5 million is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 17,285
▲ € 17,228 vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 44 days on average.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 1,735,507 | € 1,671,876 | ▼ 4% |
| Gross margin | € -4,509 | € 219,022 | - | - | |
| Profit after taxes | € 2,406,036 | € 13,903,501 | € 3,423,174 | € 8,357,527 | ▲ 144% |
| Equity | € 2,087,549 | € 15,991,050 | € 19,414,224 | € 27,771,751 | ▲ 43% |
| Total debts | € 21,511,403 | € 26,268,378 | € 22,246,613 | € 19,624,564 | ▼ 12% |
| Cash | € 11,203 | € 378,678 | € 2,052,164 | € 5,294,689 | ▲ 158% |
| Land & buildings | - | € 865,653 | € 896,644 | € 896,644 | |
| Retained profit | € 2,077,549 | € 15,981,050 | € 19,404,224 | € 27,761,751 | ▲ 43% |
| Bank debt | € 21,202,699 | € 25,728,085 | € 21,869,514 | € 18,541,431 | ▼ 15% |
| Balance sheet total | € 23,598,952 | € 42,259,427 | € 41,660,836 | € 47,396,315 | ▲ 14% |
Key figures of H & H PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to H & H PHARMACEUTICALS?
What happened at H & H PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 8.4 million (▲ 144% vs 2024). filed late Source: NBB ↗
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 2.4 million profit in 2022 to € 8.4 million profit in 2025.
Paid € 127,807 in corporate taxes since 2022.
Best year ever: 2023, with € 13.9 million profit.
Pays suppliers within 44 days on average.
A new publication or filing at H & H PHARMACEUTICALS? We notify you, reason included.
Follow H & H PHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind H & H PHARMACEUTICALS are Laurent HAVERBEKE and Koen SMESSAERT. It owns 100% of FUSION MEDICARE, 96% of Soneprophar, 95% of EXPHAR.CH and 93.7% of EXPHAR itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Avenue Thomas Edison 105
1402 Nivelles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0759.775.660
- VAT number
- BE 0759.775.660
- Registered office
- Avenue Thomas Edison 105, 1402 Nivelles
- Names & denominations
- H & H PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 December 2020
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Opslag
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied